Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Hamilton

Showing results (41-50 of 279) with videos related to

Pageof 28
Sort By:
Journal of the National Cancer Institute|April 9, 2009
Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarkerRobert J Hamilton, Elizabeth A Platz, Stephen J Freedland
European Urology|August 21, 2019
Re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607-9Gregory J Nason, Michael A S Jewett, Robert J Hamilton
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 4, 2017
28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed roboticallyJames R Hayes, Michael A S Jewett, Robert J Hamilton
Lancet (London, England)|June 1, 2025
Testicular cancerJulian Chavarriaga, Lucia Nappi, Alexandros Papachristofilou, et al.
Prostate Cancer and Prostatic Diseases|June 29, 2022
Statins and prostate cancer-hype or hope? The biological perspectiveJoseph Longo, Stephen J Freedland, Linda Z Penn, et al.
European Urology Focus|May 27, 2019
Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred OptionRobert J Hamilton, Michael A S Jewett, Padraig Warde, et al.
Annual Review of Medicine|November 6, 2013
Chemoprevention of prostate cancerGoutham Vemana, Robert J Hamilton, Gerald L Andriole, et al.
JCO Oncology Practice|June 13, 2025
Optimal Management of Stage II Seminoma: Preventing Harm While Preserving CureCiara Conduit, Aditya Bagrodia, Robert J Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Challenges Interpreting Chemoprevention Studies Using Observational DataMadhur Nayan, David N Juurlink, Antonio Finelli, et al.
Journal of the National Cancer Institute|October 30, 2008
The influence of statin medications on prostate-specific antigen levelsRobert J Hamilton, Kenneth C Goldberg, Elizabeth A Platz, et al.
Pageof 28

Showing results (41-50 of 279) with videos related to

Sort By:
Pageof 28
Journal of the National Cancer Institute|April 9, 2009
Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarkerRobert J Hamilton, Elizabeth A Platz, Stephen J Freedland
European Urology|August 21, 2019
Re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607-9Gregory J Nason, Michael A S Jewett, Robert J Hamilton
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 4, 2017
28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed roboticallyJames R Hayes, Michael A S Jewett, Robert J Hamilton
Lancet (London, England)|June 1, 2025
Testicular cancerJulian Chavarriaga, Lucia Nappi, Alexandros Papachristofilou, et al.
Prostate Cancer and Prostatic Diseases|June 29, 2022
Statins and prostate cancer-hype or hope? The biological perspectiveJoseph Longo, Stephen J Freedland, Linda Z Penn, et al.
European Urology Focus|May 27, 2019
Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred OptionRobert J Hamilton, Michael A S Jewett, Padraig Warde, et al.
Annual Review of Medicine|November 6, 2013
Chemoprevention of prostate cancerGoutham Vemana, Robert J Hamilton, Gerald L Andriole, et al.
JCO Oncology Practice|June 13, 2025
Optimal Management of Stage II Seminoma: Preventing Harm While Preserving CureCiara Conduit, Aditya Bagrodia, Robert J Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Challenges Interpreting Chemoprevention Studies Using Observational DataMadhur Nayan, David N Juurlink, Antonio Finelli, et al.
Journal of the National Cancer Institute|October 30, 2008
The influence of statin medications on prostate-specific antigen levelsRobert J Hamilton, Kenneth C Goldberg, Elizabeth A Platz, et al.
Pageof 28